APPLICANTS: Ward et al. SERIAL NO: 10/719,370

## DOCKET NO: PTS-0070US.P1 (ISIS.038CP1)

## REMARKS

Claims 1-8, 22-25, 33, 37-44, 47-54, 64-67, 70, 71, 77, 81-88 and 91-121 are pending in the instant application. The Office Action requires election of a single oligonucleotide SEQ ID NO and corresponding target gene from claims 1, 47, 70, 71, 92 and 116-119.

Applicants elect SEQ ID NO: 446, targeted to HIF1α (SEQ ID NO: 133), without traverse. Claims 47-54, 64-67, 70, 71, 77, 81-88, 91-118 and 121 are canceled herein and claim 1 is amended to remove reference to the non-elected SEQ ID NO, as required by the restriction. Claim 2 also is canceled herein. However, Applicants reserve the right to pursue the matter in a divisional application.

Claim 1 is amended to incorporate the 12 to 50 nucleobase length limitation of now canceled claim 2 and to remove the limitation on inhibiting expression of HIF1a. Claim 3 is amended to correct claim dependency. Claim 119 is amended to correct claim dependency and for clarity. New claims 122-124 added herein find basis throughout the application and claims as originally filed, for example, at pages 22-24 and 27-28 of the specification. No new matter has been added to the claims. Upon entry of this amendment, claims 1, 3-8, 22-25, 33, 37-44, 119, 120 and 122-124 will be pending.

It is believed that no fee is due with this response. However, if an additional fee is due, the Commissioner is hereby entitled to charge the fee to the Deposit Account 50-0252, referencing the above named application.

Applicants believe that the foregoing comprises a full and complete response to the Office Action of record. Accordingly, an early office action on the merits of the case is respectfully requested.

Respectfully submitted,

Registration No. 54,044

Date: May 16, 2006

ISIS Pharmaceuticals, Inc. 1896 Rutherford Rd. Carlsbad, CA 92008 Telephone: (760) 603-2777

Facsimile: (760) 603-3820